Healthcare provider profile · identity verified

Bethany Ann Wardlow, MD

Allopathic & Osteopathic Physicians|Family Medicine · JACKSON, TN · NPI 1265566483

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Bethany Ann Wardlow, MD received $38.90 in general payments during 2025 across 2 reported records.

Regeneron Healthcare Solutions, Inc. accounted for 50.1% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 3 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.

PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Eliquis by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$38.90

2 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Regeneron Healthcare Solutions, Inc.	Unresolved — no canonical attribution shown	$19.49	50.1%	1	2025
PFIZER INC.	Unresolved — no canonical attribution shown	$19.41	49.9%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$38.90	2

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
EVKEEZA Normalized: evkeeza	Biological	Regeneron Healthcare Solutions, Inc.	$19.49	1	2025
Source payment records 2025-02-20 · Regeneron Healthcare Solutions, Inc. · $19.49 · Open Payments source
ELIQUIS Normalized: eliquis	Drug	PFIZER INC.	$19.41	1	2025
Source payment records 2025-10-15 · PFIZER INC. · $19.41 · Open Payments source
NURTEC ODT Normalized: nurtec odt	Drug	PFIZER INC.	$19.41	1	2025
Source payment records 2025-10-15 · PFIZER INC. · $19.41 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
ELIQUIS eliquis	2025	Eliquis	2024	129	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
PFIZER INC. Exact reporting entity; no affiliate inference	2025	ELIQUIS open payments reported associated product	CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063	Eliquis · 2024 Exact normalized brand match · 1 Part D row	129	29

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	787	197
Amlodipine Besylate	Amlodipine Besylate	706	198
Levothyroxine Sodium	Levothyroxine Sodium	583	140
Gabapentin	Gabapentin	564	113
Pantoprazole Sodium	Pantoprazole Sodium	550	151
Lisinopril	Lisinopril	521	133
Montelukast Sodium	Montelukast Sodium	493	147
Omeprazole	Omeprazole	491	139
Furosemide	Furosemide	428	140
Losartan Potassium	Losartan Potassium	397	114
Rosuvastatin Calcium	Rosuvastatin Calcium	390	104
Simvastatin	Simvastatin	365	96
Metoprolol Tartrate	Metoprolol Tartrate	315	74
Metformin Hcl	Metformin Hcl	307	86
Carvedilol	Carvedilol	281	79
Pregabalin	Pregabalin	271	60
Quetiapine Fumarate	Quetiapine Fumarate	258	51
Metoprolol Succinate	Metoprolol Succinate	250	58
Hydrochlorothiazide	Hydrochlorothiazide	245	63
Alprazolam	Alprazolam	240	44
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	232	45
Potassium Chloride	Potassium Chloride	226	76
Trazodone Hcl	Trazodone Hcl	225	70
Zolpidem Tartrate	Zolpidem Tartrate	217	31
Clopidogrel	Clopidogrel Bisulfate	196	54
Escitalopram Oxalate	Escitalopram Oxalate	184	53
Meloxicam	Meloxicam	180	61
Diclofenac Sodium	Diclofenac Sodium	172	47
Alendronate Sodium	Alendronate Sodium	171	46
Ozempic	Semaglutide	168	39
Duloxetine Hcl	Duloxetine Hcl	163	43
Albuterol Sulfate Hfa	Albuterol Sulfate	159	54
Lorazepam	Lorazepam	159	26
Sertraline Hcl	Sertraline Hcl	159	51
Buspirone Hcl	Buspirone Hcl	152	42
Fluticasone Propionate	Fluticasone Propionate	150	57
Tramadol Hcl	Tramadol Hcl	150	31
Hydralazine Hcl	Hydralazine Hcl	135	44
Glipizide Er	Glipizide	133	35
Eliquis	Apixaban	129	29
Isosorbide Mononitrate Er	Isosorbide Mononitrate	126	26
Mounjaro	Tirzepatide	124	21
Famotidine	Famotidine	123	43
Valsartan	Valsartan	122	27
Allopurinol	Allopurinol	120	37
Tizanidine Hcl	Tizanidine Hcl	120	30
Citalopram Hbr	Citalopram Hydrobromide	119	24
Olmesartan Medoxomil	Olmesartan Medoxomil	118	35
Tamsulosin Hcl	Tamsulosin Hcl	118	31
Metformin Hcl Er	Metformin Hcl	117	30
Doxycycline Hyclate	Doxycycline Hyclate	116	91
Januvia	Sitagliptin Phosphate	113	27
Ezetimibe	Ezetimibe	112	38
Prednisone	Prednisone	108	56
Clonidine Hcl	Clonidine Hcl	99	26
Clonazepam	Clonazepam	98	16
Irbesartan	Irbesartan	98	28
Celecoxib	Celecoxib	91	28
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	91	25
Venlafaxine Hcl Er	Venlafaxine Hcl	91	24
Pravastatin Sodium	Pravastatin Sodium	87	24
Fluoxetine Hcl	Fluoxetine Hcl	81	21
Synthroid	Levothyroxine Sodium	81	21
Donepezil Hcl	Donepezil Hcl	80	17
Glimepiride	Glimepiride	75	22
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	75	16
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	75	18
Paroxetine Hcl	Paroxetine Hcl	74	14
Jardiance	Empagliflozin	73	23
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	71	18
Cephalexin	Cephalexin	70	60
Doxepin Hcl	Doxepin Hcl	70	18
Promethazine Hcl	Promethazine Hcl	70	17
Betamethasone Valerate	Betamethasone Valerate	68	34
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	68	21
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	67	18
Dicyclomine Hcl	Dicyclomine Hcl	65	15
Vitamin D2	Ergocalciferol (Vitamin D2)	65	19
Bupropion Xl	Bupropion Hcl	64	13
Farxiga	Dapagliflozin Propanediol	64	14
Pioglitazone Hcl	Pioglitazone Hcl	62	18
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	61	19
Lovastatin	Lovastatin	57	15
Spironolactone	Spironolactone	55	17
Oxybutynin Chloride	Oxybutynin Chloride	54	12
Benazepril Hcl	Benazepril Hcl	52	12
Meclizine Hcl	Meclizine Hcl	52	21
Mupirocin	Mupirocin	52	29
Fluconazole	Fluconazole	51	34
Nifedipine Er	Nifedipine	50	12
Chlorthalidone	Chlorthalidone	48	suppressed
Linzess	Linaclotide	48	14
Torsemide	Torsemide	48	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	46	16
Baclofen	Baclofen	44	19
Solifenacin Succinate	Solifenacin Succinate	44	13
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	44	suppressed
Methylprednisolone	Methylprednisolone	43	38
Nebivolol Hcl	Nebivolol Hcl	42	12
Topiramate	Topiramate	40	suppressed
Warfarin Sodium	Warfarin Sodium	40	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	39	suppressed
Ondansetron Hcl	Ondansetron Hcl	39	28
Finasteride	Finasteride	38	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	38	suppressed
Tresiba Flextouch U-200	Insulin Degludec	38	suppressed
Lansoprazole	Lansoprazole	37	suppressed
Nystatin	Nystatin	37	16
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	36	12
Esomeprazole Magnesium	Esomeprazole Magnesium	35	suppressed
Mirtazapine	Mirtazapine	35	14
Nitrofurantoin	Nitrofurantoin Macrocrystal	35	12
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	34	suppressed
Ranolazine Er	Ranolazine	34	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	33	suppressed
Atenolol	Atenolol	32	suppressed
Azithromycin	Azithromycin	32	30
Ibuprofen	Ibuprofen	32	12
Ciprofloxacin Hcl	Ciprofloxacin Hcl	31	22
Nitroglycerin	Nitroglycerin	31	13
Propranolol Hcl	Propranolol Hcl	31	suppressed
Amoxicillin	Amoxicillin	30	25
Fenofibrate	Fenofibrate	29	suppressed
Levofloxacin	Levofloxacin	29	22
Sumatriptan Succinate	Sumatriptan Succinate	29	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	28	suppressed
Estradiol	Estradiol	28	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	28	suppressed
Levetiracetam	Levetiracetam	28	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	28	suppressed
Primidone	Primidone	28	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	27	suppressed
Methocarbamol	Methocarbamol	26	suppressed
Midodrine Hcl	Midodrine Hcl	26	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	26	suppressed
Sucralfate	Sucralfate	26	suppressed
Xarelto	Rivaroxaban	26	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	25	suppressed
Megestrol Acetate	Megestrol Acetate	25	suppressed
Enalapril Maleate	Enalapril Maleate	24	suppressed
Ketoconazole	Ketoconazole	24	11
Novolin R	Insulin Regular, Human	24	suppressed
Valacyclovir	Valacyclovir Hcl	22	14
Colestipol Hcl	Colestipol Hcl	21	suppressed
Digoxin	Digoxin	20	suppressed
Ropinirole Hcl	Ropinirole Hcl	20	suppressed
Single Use Swab	Alcohol Antiseptic Pads	20	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	19	14
Gemtesa	Vibegron	19	suppressed
Labetalol Hcl	Labetalol Hcl	19	suppressed
Rizatriptan	Rizatriptan Benzoate	19	suppressed
Klor-Con M20	Potassium Chloride	18	suppressed
Memantine Hcl	Memantine Hcl	18	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	18	11
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	17	suppressed
Dilt-Xr	Diltiazem Hcl	17	suppressed
Myrbetriq	Mirabegron	17	suppressed
Naproxen	Naproxen	17	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	16	suppressed
Diazepam	Diazepam	16	suppressed
Loperamide	Loperamide Hcl	16	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	16	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	16	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	16	suppressed
Sildenafil Citrate	Sildenafil Citrate	16	suppressed
Ipratropium Bromide	Ipratropium Bromide	15	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	15	suppressed
Metronidazole	Metronidazole	15	13
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	14	suppressed
Cefdinir	Cefdinir	14	11
Glipizide	Glipizide	14	suppressed
Levemir Flexpen	Insulin Detemir	14	suppressed
Trintellix	Vortioxetine Hydrobromide	14	suppressed
Azelastine Hcl	Azelastine Hcl	13	suppressed
Cefuroxime	Cefuroxime Axetil	13	11
Dexlansoprazole Dr	Dexlansoprazole	13	suppressed
Diltiazem Hcl	Diltiazem Hcl	13	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	13	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	13	suppressed
Levemir	Insulin Detemir	13	suppressed
Metolazone	Metolazone	13	suppressed
Morphine Sulfate Er	Morphine Sulfate	13	suppressed
Nabumetone	Nabumetone	13	suppressed
Olanzapine	Olanzapine	13	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	13	suppressed
Tresiba Flextouch U-100	Insulin Degludec	13	suppressed
Ventolin Hfa	Albuterol Sulfate	13	suppressed
Zonisamide	Zonisamide	13	suppressed
Alosetron Hcl	Alosetron Hcl	12	suppressed
Carbamazepine	Carbamazepine	12	suppressed
Diclofenac Potassium	Diclofenac Potassium	12	suppressed
Telmisartan	Telmisartan	12	suppressed
Verapamil Er	Verapamil Hcl	12	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	11	suppressed
Ibu	Ibuprofen	11	suppressed
Novolog	Insulin Aspart	11	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$38.90 · 2 records	Regeneron Healthcare Solutions, Inc.	ELIQUIS, EVKEEZA, NURTEC ODT	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Eliquis play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error